Opt‐in for secondary findings as part of diagnostic whole‐exome sequencing: Real‐life experience from an international diagnostic laboratory

The discussion about the risks and benefits of offering secondary findings to individuals ongoing genome‐wide diagnostics lacks real‐life data. We studied willingness of patients/families referred to whole exome study (WES) in Blueprint Genetics (BpG), a genetic testing company with customers in over 70 countries. We detected huge differences relating to opt‐in between individuals from different countries.